TY  - JOUR
AU  - Poveda, A
AU  - Lheureux, S
AU  - Colombo, N
AU  - Cibula, D
AU  - Lindemann, K
AU  - Weberpals, J
AU  - Bjurberg, M
AU  - Oaknin, A
AU  - Sikorska, M
AU  - González-Martín, A
AU  - Madry, R
AU  - Pérez, M J Rubio
AU  - Ledermann, J
AU  - Davidson, R
AU  - Blakeley, C
AU  - Bennett, J
AU  - Barnicle, A
AU  - Škof, E
PY  - 2022
DO  - 10.1016/j.ygyno.2021.12.025
UR  - http://hdl.handle.net/10668/22547
T2  - Gynecologic oncology
AB  - The phase IIIb OPINION trial (NCT03402841) investigated olaparib maintenance monotherapy in patients without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (gBRCAm) who had platinum-sensitive relapsed ovarian cancer (PSROC) and...
LA  - en
KW  - BRCA
KW  - Maintenance
KW  - Olaparib
KW  - Ovarian cancer
KW  - BRCA1 Protein
KW  - BRCA2 Protein
KW  - Carcinoma, Ovarian Epithelial
KW  - Female
KW  - Germ Cells
KW  - Germ-Line Mutation
KW  - Humans
KW  - Maintenance Chemotherapy
KW  - Mutation
KW  - Neoplasm Recurrence, Local
KW  - Ovarian Neoplasms
KW  - Phthalazines
KW  - Piperazines
KW  - Platinum
TI  - Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
TY  - research article
VL  - 164
ER  -